Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod versus placebo in relapsing-remitting multiple sclerosis (24‑month, Poland)
2008-002096-27Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fingolimod in multiple sclerosis (MS) (3 arms), sponsored by Novartis. Primary endpoint: Annualized relapse rate. Started Jun 2008; status: completed.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2008-002096-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002096-27.